Abbas Kazimi has been appointed as the new Chief Executive Officer of Nimbus Therapeutics, effective immediately14.
Kazimi succeeds Jeb Keiper, who has stepped down from the position as part of a planned transition after serving as CEO for over 6 years14.
Kazimi joined Nimbus in 2014 and has served as Chief Business Officer since 20201.
During his tenure, Kazimi helped drive key transactions resulting in over $7 billion in upfront and milestone capital from pharmaceutical partners1.
Nimbus Therapeutics is a clinical-stage biotechnology company focused on structure-based drug discovery and development1.
The company's pipeline includes promising programs like WRN and SIK inhibitors, as well as an ongoing collaboration with Lilly1.
Nimbus utilizes a unique computational drug discovery engine to develop novel small molecule medicines1.
The leadership change comes at a pivotal time in the company's evolution, as it continues to advance its pipeline and strengthen its position in the industry14.
Sources:
1. https://www.businesswire.com/news/home/20250307658905/en/Nimbus-Therapeutics-Appoints-Abbas-Kazimi-as-Chief-Executive-Officer
4. https://endpts.com/jeb-keiper-steps-down-from-nimbus-ceo-post-business-chief-to-take-over/